Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 2/2009

Open Access 01-04-2009 | Research

Markers of collagen synthesis and degradation are increased in serum in severe sepsis: a longitudinal study of 44 patients

Authors: Fiia Gäddnäs, Marjo Koskela, Vesa Koivukangas, Juha Risteli, Aarne Oikarinen, Jouko Laurila, Juha Saarnio, Tero Ala-Kokko

Published in: Critical Care | Issue 2/2009

Login to get access

Abstract

Introduction

Sepsis-related multiple organ dysfunction is a common cause of death in the intensive care unit. The effect of sepsis on markers of tissue repair is only partly understood. The aim of this study was to measure markers of collagen synthesis and degradation during sepsis and investigate the association with disease severity and outcome.

Methods

Forty-four patients with severe sepsis participated in the study and 15 volunteers acted as controls. Blood samples were collected for 10 days after the first sepsis-induced organ dysfunction and after three and six months. Procollagen type I and III aminoterminal propeptides (PINP and PIIINP) and cross-linked telopeptides of type I collagen (ICTP) were measured.

Results

The PIIINP concentration was elevated in the septic patients (8.8 ug/L, 25th to 75th percentile = 6.8 to 26.0) when compared with controls (3.0 ug/L, 25th to 75th percentile = 2.7 to 3.3; P < 0.001) on day one. Maximum serum PIIINP concentrations during sepsis were higher in non-survivors compared with survivors (26.1 ug/L, 25th to 75th percentile = 18.7 to 84.3; vs. 15.1 ug/L, 25th to 75th percentile = 9.6 to 25.5; P = 0.033) and in multiple organ failure (MOF) compared with multiple organ dysfunction syndrome (MODS) (24.2 ug/L, 25th to 75th percentile = 13.4 to 48.2; vs. 8.9 ug/L, 25th to 75th percentile = 7.4 to 19.4; P = 0.002). Although the PINP values of the septic patients remained within the laboratory reference values, patients with MOF had higher values than patients with MODS (79.8, 25th to 75th percentile = 44.1 to 150.0; vs.40.4, 25th to 75th percentile = 23.6 to 99.3; P = 0.007). Day one ICTP levels were elevated in septic patients compared with the controls (19.4 ug/L, 25th to 75th percentile = 12.0 to 29.8; vs. 4.1 ug/L, 25th to 75th percentile = 3.4 to 5.0; P < 0.001).

Conclusions

Markers of collagen metabolism are increased in patients with severe sepsis and can be investigated further as markers of disease severity and outcome.
Appendix
Available only for authorised users
Literature
1.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655.CrossRefPubMed
2.
Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348: 138-150.CrossRefPubMed
3.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31: 1250-1256.CrossRefPubMed
4.
Haukipuro K, Risteli L, Kairaluoma MI, Risteli J: Aminoterminal propeptide of type III procollagen in healing wound in humans. Ann Surg 1987, 206: 752-756.PubMedCentralCrossRefPubMed
5.
Petri JB, Konig S, Haupt B, Haustein UF, Herrmann K: Molecular analysis of different phases in human wound healing. Exp Dermatol 1997, 6: 133-139.CrossRefPubMed
6.
Jensen LT, Horslev-Petersen K, Toft P, Bentsen KD, Grande P, Simonsen EE, Lorenzen I: Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation 1990, 81: 52-57.CrossRefPubMed
7.
Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A: Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998, 158: 1432-1441.CrossRefPubMed
8.
Keller F, Rehbein C, Schwarz A, Fleck M, Hayasaka A, Schuppan D, Offermann G, Hahn EG: Increased procollagen III production in patients with kidney disease. Nephron 1988, 50: 332-337.CrossRefPubMed
9.
Moller S, Hansen M, Hillingso J, Jensen JE, Henriksen JH: Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism. Gut 1999, 44: 417-423.PubMedCentralCrossRefPubMed
10.
Zhang K, Garner W, Cohen L, Rodriguez J, Phan S: Increased types I and III collagen and transforming growth factor-beta 1 mRNA and protein in hypertrophic burn scar. J Invest Dermatol 1995, 104: 750-754.CrossRefPubMed
11.
Weber KT: Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997, 17: 467-491.PubMed
12.
Waydhas C, Nast-Kolb D, Trupka A, Lenk S, Duswald KH, Schweiberer L, Jochum M: Increased serum concentrations of procollagen type III peptide in severely injured patients: an indicator of fibrosing activity? Crit Care Med 1993, 21: 240-247.CrossRefPubMed
13.
Clark JG, Milberg JA, Steinberg KP, Hudson LD: Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann Intern Med 1995, 122: 17-23.CrossRefPubMed
14.
Wenisch C, Graninger W, Schonthal E, Rumpold H: Increased serum concentrations of the carboxy-terminal cross-linked telopeptide of collagen type I in patients with Gram-negative septicaemia. Eur J Clin Invest 1996, 26: 237-239.CrossRefPubMed
15.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines, Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32: 858-873.CrossRefPubMed
16.
Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26: 1793-1800.CrossRefPubMed
17.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22: 707-710.CrossRefPubMed
18.
Risteli Juha RL: Extracellular matrix metabolites in body fluids. In In Connective tissue and its heritable disorders: molecular, genetic and medical aspects. 2nd edition. Edited by: Royce PM, Steinmann B. New York: Wiley-liss Inc; 2002:1141-1160.CrossRef
19.
Marshall RP, Bellingan G, Webb S, Puddicombe A, Goldsack N, McAnulty RJ, Laurent GJ: Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med 2000, 162: 1783-1788.CrossRefPubMed
20.
Risteli J, Risteli L: Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995, 22: 77-81.CrossRefPubMed
21.
Nøjgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U: Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003, 39: 179-186.CrossRefPubMed
22.
Bentsen KD, Boesby S, Kirkegaard P, Hansen CP, Jensen SL, Horslev-Petersen K, Lorenzen I: Is the aminoterminal propeptide of type III procollagen degraded in the liver? A study of type III procollagen peptide in serum during liver transplantation in pigs. J Hepatol 1988, 6: 144-150.CrossRefPubMed
23.
Jensen LT, Blaehr H, Andersen CB, Risteli J, Lorenzen I: Metabolism of the aminoterminal propeptide of type III procollagen in cultures of human proximal tubular cells. Scand J Clin Lab Invest 1992, 52: 1-8.CrossRefPubMed
24.
Ohyama K, Seyer JM, Raghow R, Kang AH: A factor from damaged rat kidney stimulates collagen biosynthesis by mesangial cells. Biochim Biophys Acta 1990, 1053: 173-178.CrossRefPubMed
25.
Kanangat S, Postlethwaite A, Hasty K, Kang A, Smeltzer M, Appling W, Schaberg D: Induction of multiple matrix metalloproteinases in human dermal and synovial fibroblasts by Staphylococcus aureus: implications in the pathogenesis of septic arthritis and other soft tissue infections. Arthritis Res Ther 2006, 8: R176.PubMedCentralCrossRefPubMed
26.
Dawes KE, Gray AJ, Laurent GJ: Thrombin stimulates fibroblast chemotaxis and replication. Eur J Cell Biol 1993, 61: 126-130.PubMed
27.
Chambers RC, Dabbagh K, McAnulty RJ, Gray AJ, Blanc-Brude OP, Laurent GJ: Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 1998, 333: 121-127.PubMedCentralCrossRefPubMed
28.
Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A: Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001, 276: 45184-45192.CrossRefPubMed
29.
Duhamel-Clerin E, Orvain C, Lanza F, Cazenave JP, Klein-Soyer C: Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol 1997, 17: 1931-1938.CrossRefPubMed
30.
Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA: Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol 2008, 172: 309-320.PubMedCentralCrossRefPubMed
31.
Maish GO 3rd, Shumate ML, Ehrlich HP, Cooney RN: Tumor necrosis factor binding protein improves incisional wound healing in sepsis. J Surg Res 1998, 78: 108-117.CrossRefPubMed
32.
Thornton SC, Por SB, Walsh BJ, Penny R, Breit SN: Interaction of immune and connective tissue cells: I. The effect of lymphokines and monokines on fibroblast growth. J Leukoc Biol 1990, 47: 312-320.PubMed
33.
Budinger GR, Chandel NS, Donnelly HK, Eisenbart J, Oberoi M, Jain M: Active transforming growth factor-beta1 activates the procollagen I promoter in patients with acute lung injury. Intensive Care Med 2005, 31: 121-128.CrossRefPubMed
34.
Laun RA, Schroder O, Schoppnies M, Roher HD, Ekkernkamp A, Schulte KM: Transforming growth factor-beta1 and major trauma: time-dependent association with hepatic and renal insufficiency. Shock 2003, 19: 16-23.CrossRefPubMed
35.
Haukipuro K, Risteli L, Kairaluoma MI, Risteli J: Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings. Surgery 1990, 107: 381-388.PubMed
36.
Oikarinen A, Autio P, Vuori J, Vaananen K, Risteli L, Kiistala U, Risteli J: Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol 1992, 126: 172-178.CrossRefPubMed
37.
Fahling M, Mrowka R, Steege A, Nebrich G, Perlewitz A, Persson PB, Thiele BJ: Translational control of collagen prolyl 4-hydroxylase-alpha(I) gene expression under hypoxia. J Biol Chem 2006, 281: 26089-26101.CrossRefPubMed
38.
Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA: Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol 2008, 125: 240-245.CrossRefPubMed
39.
Sener G, Sehirli O, Cetinel S, Ercan F, Yuksel M, Gedik N, Yegen BC: Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast. Prostaglandins Leukot Essent Fatty Acids 2005, 73: 453-462.CrossRefPubMed
40.
Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, Lukashev D, Bittmann I, Sitkovsky MV: Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005, 3: e174.PubMedCentralCrossRefPubMed
Metadata
Title
Markers of collagen synthesis and degradation are increased in serum in severe sepsis: a longitudinal study of 44 patients
Authors
Fiia Gäddnäs
Marjo Koskela
Vesa Koivukangas
Juha Risteli
Aarne Oikarinen
Jouko Laurila
Juha Saarnio
Tero Ala-Kokko
Publication date
01-04-2009
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2009
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc7780

Other articles of this Issue 2/2009

Critical Care 2/2009 Go to the issue

Commentary

Sepsis-associated delirium: the pro and con of C5a blockade

Review

Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage – from theory to practice

Letter

Two devils: hypernatremia and hyponatremia can show faces to the same patient in the intensive care unit

Review

Clinical review: Ventilatory strategies for obstetric, brain-injured and obese patients

Erratum

Erratum to: Nitrogen washout/washin, helium dilution and computed tomography in the assessment of end expiratory lung volume

Research

Assessment of cardiac output changes using a modified FloTrac/Vigileo™ algorithm in cardiac surgery patients